{"product_id":"pendulum-metabolic-daily-pro-30-capsules-metabolism-gut-health-probiotic-emis","title":"Pendulum Metabolic Daily Pro (30 Capsules) | Metabolism \u0026 Gut Health Probiotic | EMIS+","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e Pendulum Metabolic Daily Pro is a five-strain medical probiotic capsule designed by Pendulum Therapeutics for the dietary management of metabolic and gut health. It contains live Akkermansia muciniphila WB-STR-0001 alongside Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii (formerly Eubacterium hallii) and Bifidobacterium infantis — a butyrate- and mucin-producing consortium implicated in glucose regulation, gut-barrier integrity and short-chain fatty acid (SCFA) signalling. The same five-strain platform underpins Pendulum's published 12-week, multi-site, double-blind, placebo-controlled randomised trial in adults with type 2 diabetes, which reported a 0.6 percentage-point reduction in HbA1c and a 33% reduction in post-prandial glucose excursions versus placebo.\u003c\/div\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eMetabolic Daily Pro is the practitioner channel formulation of Pendulum Therapeutics' multi-strain probiotic platform, targeted at adults seeking adjunctive nutritional support for metabolic health. The formulation is a proprietary \"next-generation\" probiotic, distinguished from conventional Lactobacillus\/Bifidobacterium products by the inclusion of strict-anaerobe colonic species — most notably Akkermansia muciniphila — that have historically been difficult to manufacture and stabilise in oral dosage form.\u003c\/p\u003e\n\u003cp\u003eThe five strains were selected for their complementary mechanisms in the gut: Akkermansia muciniphila supports mucin layer turnover and intestinal-barrier integrity; Clostridium butyricum and Anaerobutyricum hallii produce butyrate, the principal SCFA energy substrate of colonocytes; Clostridium beijerinckii contributes to acetate\/butyrate production; and Bifidobacterium infantis supports infant-type bifidobacterial cross-feeding. Capsules are delivered in an acid-resistant shell to protect viability through gastric transit. The product is intended to be used as part of a balanced diet and is not a substitute for prescribed glucose-lowering therapy.\u003c\/p\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable style=\"border-collapse: collapse; width: 100%;\" cellspacing=\"0\" cellpadding=\"6\" border=\"1\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eManufacturer\u003c\/th\u003e\n\u003ctd\u003ePendulum Therapeutics, Inc. (United States)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eProduct\u003c\/th\u003e\n\u003ctd\u003eMetabolic Daily Pro — multi-strain probiotic capsule (practitioner channel)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003ePack size\u003c\/th\u003e\n\u003ctd\u003e30 capsules per bottle (one-month supply at 1 capsule\/day)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eActive strains\u003c\/th\u003e\n\u003ctd\u003eAkkermansia muciniphila WB-STR-0001; Clostridium butyricum; Clostridium beijerinckii; Anaerobutyricum hallii; Bifidobacterium infantis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eMechanism class\u003c\/th\u003e\n\u003ctd\u003eMucin-degrading and butyrate-producing consortium; SCFA and gut-barrier supportive\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eDosage form\u003c\/th\u003e\n\u003ctd\u003eAcid-resistant capsule (gastric-protective shell)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eDietary attributes\u003c\/th\u003e\n\u003ctd\u003eVegan capsule shell; gluten-free; non-GMO; soy-free; dairy-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eRefrigerate at 2–8°C to preserve viable cell count; protect from heat and humidity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eManufacturing standards\u003c\/th\u003e\n\u003ctd\u003eManufactured under cGMP (US FDA 21 CFR Part 111 dietary supplement regulations); supplier facilities operate to NSF\/IFS food-safety standards\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eRegulatory positioning\u003c\/th\u003e\n\u003ctd\u003eMarketed as a medical probiotic dietary supplement in the United States. In Singapore, classified by HSA as a health supplement under the Health Products Act and not as a registered therapeutic product or medical device. Not intended to diagnose, treat, cure, or prevent any disease.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003eKey clinical evidence\u003c\/th\u003e\n\u003ctd\u003ePerraudeau et al., BMJ Open Diabetes Research \u0026amp; Care 2020 — 12-week, randomised, double-blind, placebo-controlled trial; HbA1c −0.6 percentage points and post-prandial glucose AUC −33% versus placebo in adults with type 2 diabetes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eKey Applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAdjunctive nutritional support of glycaemic and post-prandial glucose response in adults with diet-controlled or metformin-managed type 2 diabetes (under clinician supervision).\u003c\/li\u003e\n\u003cli\u003eMicrobiome support in adults with metabolic syndrome features — central adiposity, dyslipidaemia, prediabetes — as part of a structured lifestyle programme.\u003c\/li\u003e\n\u003cli\u003eRestoration of mucin-degrading and butyrate-producing bacterial niches following broad-spectrum antibiotic exposure.\u003c\/li\u003e\n\u003cli\u003eAdjunctive support after weight-loss interventions (caloric restriction, GLP-1 receptor agonist therapy, bariatric surgery) where intestinal barrier and SCFA function are clinically relevant.\u003c\/li\u003e\n\u003cli\u003ePractitioner-led functional and integrative medicine programmes addressing gut-barrier dysfunction.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eWhat clinical evidence supports the formulation?\u003c\/strong\u003e\u003cbr\u003eThe five-strain Pendulum platform was evaluated in a 12-week, multi-site, double-blind, randomised, placebo-controlled clinical trial in adults with type 2 diabetes (Perraudeau et al., 2020, BMJ Open Diabetes Research \u0026amp; Care). The active arm achieved a statistically significant reduction in HbA1c of approximately 0.6 percentage points and a 33% reduction in post-prandial glucose AUC versus placebo on background standard care.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eHow does this differ from conventional probiotics?\u003c\/strong\u003e\u003cbr\u003eStandard probiotics are dominated by Lactobacillus and Bifidobacterium strains, which colonise the small intestine. Metabolic Daily Pro contains strict colonic anaerobes — including Akkermansia muciniphila — whose mucin-degradation and butyrate-production pathways are mechanistically tied to gut-barrier integrity and metabolic homeostasis rather than simple lactic-acid fermentation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhy does the product require refrigeration?\u003c\/strong\u003e\u003cbr\u003eStrict anaerobes such as Akkermansia muciniphila are sensitive to oxygen, heat and humidity. Refrigeration at 2–8°C and acid-resistant encapsulation preserve viable colony-forming units (CFU) over the labelled shelf life. Storage at room temperature for short periods during transit is acceptable per the manufacturer's stability data.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIs it safe with metformin or other glucose-lowering therapy?\u003c\/strong\u003e\u003cbr\u003eThe Pendulum trial enrolled patients on stable metformin and standard care. As with any dietary supplement that may influence glycaemic response, patients on insulin, sulphonylureas or GLP-1 receptor agonists should be reviewed by their treating clinician for hypoglycaemia risk and dose-titration considerations. The product is not a substitute for prescribed therapy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat is the regulatory status in Singapore?\u003c\/strong\u003e\u003cbr\u003eIn Singapore the product is supplied as a health supplement under the Health Products Act and is not registered as a therapeutic product or medical device with the Health Sciences Authority (HSA). The manufacturer operates under US FDA 21 CFR Part 111 cGMP requirements for dietary supplements. Essential Medical International Supplies Pte Ltd (emis.asia) is the authorised reseller and recommends use under qualified healthcare-professional guidance.\u003c\/p\u003e","brand":"Pendulum","offers":[{"title":"Default Title","offer_id":43510078144590,"sku":null,"price":115.0,"currency_code":"SGD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0613\/3763\/2846\/files\/emisproductlisting_74.jpg?v=1773109318","url":"https:\/\/www.emis.asia\/products\/pendulum-metabolic-daily-pro-30-capsules-metabolism-gut-health-probiotic-emis","provider":"EMIS +","version":"1.0","type":"link"}